olatorepatide vs VK2735

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline

olatorepatide

Developed by Regeneron Pharmaceuticals under a licence from Hansoh Pharmaceutical Group

Phase 3 in Obesitypeptide
Reliable signal

NCT06839664 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial (n=604). The co-primary endpoints, percent weight change and the proportion achieving at least 5% weight loss at week 48, were both met: participants lost up to 19.3% of body weight and up to 97.2% achieved at least 5% weight loss, both significantly better than placebo.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: January 2028 · NCT07685808 (registry estimate)

Reported efficacy

Percent Change from Baseline in Body Weight (Baseline, week 48); Percentage of Participants Who Achieve weight loss≥ 5% from Baseline (Baseline, week 48): Co-primary endpoints met at Week 48: up to 19.3% mean weight loss with olatorepatide from baseline (dose range 5/10/15mg); up to 97.2% of participants achieved ≥5% weight loss, statistically significant vs placebo. (met)

Result source: NCT06839664

VK2735

Developed by Viking Therapeutics

Phase 3 in Obesitypeptide
Reliable signal

NCT06828055 · Phase 2 · completed

This randomized, triple-blind, placebo-controlled Phase 2 trial (n=280) in adults with obesity found that oral VK2735 produced significantly greater weight loss than placebo at 13 weeks, up to 12.2% versus 1.3% (placebo-adjusted 10.9%, p<0.0001).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2027 · NCT07838740 (registry estimate)

Reported efficacy

Percent (relative) change from baseline in body weight after 13 weeks of treatment: Primary endpoint (mean % body weight change from baseline at 13 weeks): up to -12.2% with oral VK2735 vs -1.3% placebo; placebo-adjusted -10.9%, p<0.0001 (met)

Result source: NCT06828055

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointolatorepatideVK2735
Body weight, % change—Not posted · NCT06839664—Trial running · NCT07104500
Weight loss of 5% or more—Not posted · NCT06839664—Trial running · NCT07104500
Weight loss of 10% or more—Not posted · NCT06839664—Trial running · NCT07104500
Waist circumference, change (cm)—Not posted · NCT06839664—Trial running · NCT07104500

Body weight, % change

olatorepatide
—Not posted · NCT06839664
VK2735
—Trial running · NCT07104500

Weight loss of 5% or more

olatorepatide
—Not posted · NCT06839664
VK2735
—Trial running · NCT07104500

Weight loss of 10% or more

olatorepatide
—Not posted · NCT06839664
VK2735
—Trial running · NCT07104500

Waist circumference, change (cm)

olatorepatide
—Not posted · NCT06839664
VK2735
—Trial running · NCT07104500
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

VK2735
Primary endpoint (mean % body weight change from baseline at 13 weeks): up to -12.2% with oral VK2735 vs -1.3% placebo; placebo-adjusted -10.9%, p<0.0001 NCT06828055 · Phase 2 · design grade: strong · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

olatorepatide

Weight 19.3% @ 48wk
percent change · % of baseline
No placebo or comparator arm
NCT06839664 · Phase 3 · sponsor-reported, not registry data
Weight Loss 5% 97.2% @ 48wk
responder rate · % of participants
No placebo or comparator arm
NCT06839664 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: olatorepatide's landscape · VK2735's landscape